IBAB Ion Beam Applications SA

IBA signs contract to install Georgia’s first proton therapy center

IBA signs contract to install Georgia’s first proton therapy center

IBA signs contract to install Georgia’s first proton therapy center

Proteus®ONE contract worth over EUR 35 million to IBA

Backlog at record level of EUR 1.1 billion

Balance sheet strengthened with completion of debt refinancing

Louvain-La-Neuve, Belgium, 28 January 2020 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract and received a major down payment for a Proteus®ONE solution financed by the International Charity Foundation Cartu, the largest charity organization in Georgia. The contract includes a clinical Proteus®ONE solution and an additional cyclotron that will be dedicated to scientifc research. The proton therapy center will be installed at the campus of the new Kutaisi International University (KIU), located in Kutaisi, Georgia and the first patient treatment is scheduled for 2024.

The contract includes a long-term operation and maintenance agreement and the typical end-user price for a Proteus®ONE* solution with a maintenance contract is between EUR 35 and 40 million. IBA has begun to recognize revenue for the contract in the 2019 financial year.

Including this order, IBA sold eight rooms in 2019, bringing its backlog to a record high of EUR 1.1 billion. The Company has also finalized the refinancing of its credit lines with a term loan facility and a revolving loan facility for a total of EUR 67 million, further strengthening its balance sheet and its capacity to continue investment in innovative research and development to drive future growth.

Olivier Legrain, Chief Executive Officer of IBA, commented: “This collaboration with Cartu Foundation to bring proton therapy to Georgia further increases the reach of proton therapy around the world and demonstrates the appeal of IBA’s product offering. IBA’s Proteus®ONE solution is a unique and truly compact intensity modulated proton therapy (IMPT) system and, alongside its open gantry and track record of short installation time, is the solution of choice for an increasing number of hospitals globally. We look forward to working closely with the Cartu Foundation and the new Kutaisi International University to provide greater access to proton therapy for cancer patients in Georgia and the South Caucasus, and facilitate greater research into modalities such as FLASH irradiation and ARC Therapy in proton therapy.”

Alexander Tevzadze, Rector of Kutaisi International University commented: “Proton therapy is considered as a superior form of radiotherapy and represents a better treatment choice for many forms of cancer. We are excited to partner with IBA to bring proton therapy to Georgia as part of the proton therapy center at the Kutaisi International University. The unique configuration of IBA’s equipment and the additional cyclotron will offer us a comprehensive range of applications and will allow us to be at the forefront of proton therapy development and research, which perfectly fits the mission of Kutaisi International University. Also, our patients will be able to stay closer to home to receive treatment that was previously unavailable in the region.”

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1400 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

About International Charity Foundation Cartu

The International Charity Foundation Cartu (the Cartu Foundation) is the largest charitible organization in Georgia. Created and funded by the former Prime Minister of Georgia, Bidzina Ivanishvili, Cartu Foundation has implemented a wide range of projects for the benefit of the Georgian people costing over USD 3 billion over the last 20 years. The new Kutaisi International University was initiated by the Cartu Foundation. The University will include facilities for students and teachers across a 153-hectare territory. The campus, together with its proton therapy center, represents a total investment of 1 billion Euro, and is one of the largest educational and research projects initiated and funded by the Cartu Foundation.

For further information, please contact:

IBA

Soumya Chandramouli

Chief Financial Officer



Thomas Ralet

Head of Corporate Communication



For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Angela Gray, Lucy Featherstone, Lizzie Seeley

+44 (0) 20 3709 5700

Attachment

EN
28/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Heineken: No respite / IBA: Attractive €15-20m acquisition in radio pharma.

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Lewi

Morning Notes : BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, N...

: BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, NXFIL NA, ENRGY BB

 PRESS RELEASE

IBA acquires ORA expanding its strategic leadership in Nuclear Medicin...

IBA acquires ORA expanding its strategic leadership in Nuclear Medicine Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium. This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and more personalized patient...

 PRESS RELEASE

Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en m...

Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en médecine nucléaire Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine nucléaire, acquiert ORA, pionnier mondial de la radiochimie, basé en Belgique. Cette acquisition illustre l'engagement à long terme d'IBA dans le domaine en pleine expansion et à fort potentiel de la médecine nucléaire. Elle consolide la position d'IBA à l’avant-garde de l'innovation en oncologie de précision, p...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

IBA: The Lancet Journal on proton therapy new standard of care for patients with Oropharyngeal cancer. Events Calendar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch